An Early Phase 1 interventional study of [F18]-FDDNP in Progressive Supranuclear Palsy, Multi-System Atrophy and Parkinsonism, sponsored by Fundacion Clinic per a la Recerca Biomédica. Completed at 1 site in Spain. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-02-04.
Sponsored by Fundacion Clinic per a la Recerca Biomédica · Early Phase 1 and Interventional
Among 12 studies in Supranuclear Palsy, Progressive with a site in Spain — 3 open to participants now, 5 under way, 1 of them phase 3. Supranuclear Palsy, Progressive · Spain.
Among the 12 studies in Supranuclear Palsy, Progressive with a site in Spain, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2013, is one of 3 in phase 1, and was the 2nd registered.
171 studies on the registry are indexed under Supranuclear Palsy, Progressive; 51 are open to participants now.
This study's enrollment of 40 is close to the median of 43 across 102 interventional studies indexed under Supranuclear Palsy, Progressive.
Browse Supranuclear Palsy, Progressive studies →3 of the 12 studies in Supranuclear Palsy, Progressive with a site in Spain are open now.
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 38 Supranuclear Palsy, Progressive studies recruiting now, 22 (58%) set no upper age limit and 2 (5%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 3
First in 2009; this study’s year is marked. 1 started in 2013.
Median enrollment 146 across the 11 interventional studies, 350 across the 1 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
10 of 12 have an industry lead sponsor. The 10 most frequent:
Fundacion Clinic per a la Recerca Biomédica is the lead sponsor of 64 studies on the registry; 27 are open to participants now.
Fundacion Clinic per a la Recerca Biomédica has 1 study filed under Supranuclear Palsy, Progressive — fewer than ten, so there is no comparison to draw.
1 of the studies in Supranuclear Palsy, Progressive with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06355531Ferrer Internacional S.A.A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) | 2026-11 |
Among the 12 studies in Supranuclear Palsy, Progressive with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
The PET tracer [F18]-FDDNP has a specific affinity for lesions containing tau protein.
The study consists of two phases:
We hypothesized that:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2-(1-{6-\[(2-\[F-18\]fluoroethyl) (methyl)amino\]-2-naphthyl} ethylidene) malononitrile Radiopharmaceutical tracer, intravenous, single dose of 360+/-20 megabecquerel
Drug: [F18]-FDDNP
radiopharmaceutical tracer
Also known as: 22-(1-{6-[(2-[F-18]fluoroethyl) (methyl)amino]-2-naphthyl} ethylidene) malononitrile
To assess the Relative Volume of Distribution of [18F]-FDDNP in individuals with unclassifiable parkinsonism, and to try to correlate their eventual clinical diagnosis with baseline PET findings.
Time frame: 18 months
to assess the uptake of [18F]-FDDNP in cases clinically defined of progressive supranuclear palsy and multi-system atrophy
Time frame: Baseline assessment
To assess the ability to detect in vivo underlying tau pathology in unclassifiable parkinsonism by means of PET -[18F]-FDDNP.
Time frame: 18 months
The record gives a start of Mar 2013, a primary completion of Dec 2015 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Supranuclear Palsy, Progressive →
Fundacion Clinic per a la Recerca Biomédica